Utrophin (UTRN) is a cytoplasmic protein that anchors the cytoskeleton to the plasma membrane through interactions with actin, vinculin, and integrins, functioning as a structural paralogue of dystrophin 1. In normal muscle, utrophin expression is tightly regulated, but it undergoes transcriptional upregulation in Duchenne muscular dystrophy (DMD) patients through an mRNA decay-based compensatory mechanism triggered by dystrophin dysfunction 2. This upregulation occurs even when dystrophin-encoding mRNA is degraded via nonsense-mediated decay, highlighting a genetic compensation pathway 2. Clinically, utrophin upregulation has profound therapeutic implications for DMD. In dystrophin-deficient models, elevated utrophin expression improves skeletal and cardiac muscle function, reduces calcium dysregulation, and extends survival 2-3 fold 3. In human cardiomyocytes derived from DMD patients, utrophin overexpression restores physiological properties including afterhyperpolarization and calcium oscillation patterns, compensating for dystrophin loss 1. Similarly, transgenic utrophin expression and microutrophin variants demonstrate functional restoration of muscle performance with reduced immunogenicity compared to dystrophin substitutes 4. The mdx/utrn-/- mouse model, lacking both proteins, displays severe respiratory dysfunction mirroring human DMD pathology, confirming utrophin's essential compensatory role 5. Beyond DMD, utrophin acts as a tumor suppressor in breast cancer, with decreased expression correlating with poor prognosis and tamoxifen resistance 6.